These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 17646232

  • 1. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
    Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW.
    Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
    [Abstract] [Full Text] [Related]

  • 2. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW.
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [Abstract] [Full Text] [Related]

  • 3. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
    Creaney J, Musk AW, Robinson BW.
    J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
    [Abstract] [Full Text] [Related]

  • 4. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [Abstract] [Full Text] [Related]

  • 5. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?
    Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW.
    Lung Cancer; 2013 Apr; 80(1):39-44. PubMed ID: 23357461
    [Abstract] [Full Text] [Related]

  • 6. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
    Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T.
    Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
    [Abstract] [Full Text] [Related]

  • 7. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
    Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW.
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
    [Abstract] [Full Text] [Related]

  • 8. Serum and pleural fluid biomarkers for mesothelioma.
    Creaney J, Robinson BW.
    Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
    [Abstract] [Full Text] [Related]

  • 9. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW.
    Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
    [Abstract] [Full Text] [Related]

  • 10. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND.
    Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN.
    Asian Pac J Cancer Prev; 2010 Feb; 11(1):111-6. PubMed ID: 20593939
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G, Tada Y, Shimada H, Metintas S, Ito M, Hiroshima K, Tagawa M, Metintas M.
    BMC Cancer; 2017 Mar 23; 17(1):212. PubMed ID: 28335760
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
    Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW.
    Dis Markers; 2013 Mar 23; 35(2):119-27. PubMed ID: 24167356
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.